HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s stock price was up 8.3% during mid-day trading on Tuesday . The stock traded as high as $12.72 and last traded at $13.15. Approximately 48,337 shares changed hands during trading, a decline of 55% from the average daily volume of 107,565 shares. The stock had previously closed at $12.14.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
View Our Latest Analysis on HUTCHMED
HUTCHMED Trading Up 9.5 %
The stock has a 50-day simple moving average of $14.75 and a two-hundred day simple moving average of $16.16. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in HCM. Public Employees Retirement System of Ohio grew its stake in shares of HUTCHMED by 49.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after buying an additional 899 shares during the last quarter. Bank of America Corp DE grew its position in HUTCHMED by 40.4% during the 4th quarter. Bank of America Corp DE now owns 22,723 shares of the company's stock worth $327,000 after acquiring an additional 6,540 shares during the last quarter. Jane Street Group LLC grew its position in HUTCHMED by 54.7% during the 4th quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock worth $1,405,000 after acquiring an additional 34,473 shares during the last quarter. Marshall Wace LLP purchased a new position in HUTCHMED in the 4th quarter worth approximately $261,000. Finally, Barclays PLC lifted its position in HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after purchasing an additional 2,255 shares during the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
